한글목차

• 2024년, GlobalData의 CU에 관한 역학 예측에서 다루고 있는 16개국에서 CU로 진단되는 환자는 6,000만 명을 넘을 것으로 예측됩니다.
• 현재 CSU 시장의 주요 기업은 듀픽센트(Dupixent, 듀필루맙)를 보유한 Regeneron/Sanofi와 조레아(Zorea, 오말리주맙)를 보유한 Genentech/Novartis 등이 있습니다.
• CU의 파이프라인에는 42개의 분자가 있습니다. 3단계 파이프라인은 3개, 2단계 파이프라인은 17개입니다.
• 지난 10년간 미국은 223개 CU 임상시험 기관으로 가장 많았고, 중국은 186개 기관으로 그 뒤를 이었습니다.
• 지난 10년간 아시아태평양, 북미, 유럽에서는 인수합병이 주류를 이루었습니다.

세계의 만성 두드러기 시장에 대해 조사분석했으며, 질환 상황, 출시 약품과 파이프라인 약품의 평가, 현재와 향후 경쟁 상황 등을 제공하고 있습니다.

목차

제1장 목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약품의 평가

• 주요 출시 약품
• 개요 : 작용기서별
• 개요 : 분자 유형별
• 제품 개요와 판매 예측

제5장 가격결정과 상환 평가

• 연간 치료비
• 가격결정과 상환까지의 시간

제6장 파이프라인 약품 평가

• 중기부터 후기 파이프라인 약품
• 개요 : 개발 단계별
• 개요 : 작용기서별
• 개요 : 분자 유형별
• 약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
• 치료 영역과 적응증 고유 PTSR와 LoA

제7장 임상시험의 평가

• 과거의 개요
• 개요 : 단계별
• 개요 : 현황별
• 개요 : 단계별(진행중/계획 시험)
• 가상 컴포넌트에 의한 시험
• 지역별 시험의 개요
• 단일국/다국간 시험 : 지역별
• 스폰서 상위 20사와 내역 : 단계별
• 스폰서 상위 20사와 내역 : 현황별
• 개요 : 엔드포인트 현황별
• 개요 : 인종/민족별
• 등록 데이터
• 시험 시설 상위 20개국
• 세계의 상위 20 시설
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴 : 지역별
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in chronic urticaria therapeutics.

• In 2024, more than 60 million diagnosed prevalent cases of CU are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for CU.
• The key players in the current CSU market include Regeneron/Sanofi with Dupixent (dupilumab) and Genentech/Novartis with Xolair (omalizumab).
• There are 42 molecules in the pipeline for CU. The Phase III pipeline consists of three drugs, followed by 17 drugs in Phase II.
• Over the past 10 years, the US has hosted the highest number of trial sites for CU, at 223 trial sites, followed by China with 186 trial sites.
• During the past decade, In Asia-Pacific, North America, and Europe, acquisition deals were more prevalent.

Scope

GlobalData's Chronic urticaria: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Chronic urticaria market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Chronic urticaria market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer